18β-GA-3-O-β-Man for COVID-19

 18β-GA-3-O-β-Man has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 200+ treatments. We have not reviewed 18β-GA-3-O-β-Man in detail.
Liao et al., Glycosylated 18β-glycyrrhetinic acid derivatives as promising inhibitors of the SARS-CoV-2 main protease, RSC Advances, doi:10.1039/d5ra04664e
Enzymatically glycosylated 18β-glycyrrhetinic acid derivatives potently inhibit SARS-CoV-2 Mpro, with enhanced solubility and unique sugar-driving binding, highlighting their potential as cost-effective antiviral candidates.